Andrzej Januszewski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7657741/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Research and Clinical Practice, 2022, 186, 109835.	1.1	1
2	Skin autofluorescence in people with type 1 diabetes and people without diabetes: An eightâ€decade crossâ€sectional study with evidence of accelerated aging and associations with complications. Diabetic Medicine, 2021, 38, e14432.	1.2	8
3	Imaging the eye and its relevance to diabetes care. Journal of Diabetes Investigation, 2021, 12, 897-908.	1.1	5
4	Machine learning workflows identify a microRNA signature of insulin transcription in human tissues. IScience, 2021, 24, 102379.	1.9	17
5	Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Scientific Reports, 2021, 11, 11727.	1.6	16
6	The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research, 2021, 18, 147916412110325.	0.9	3
7	Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes. Scientific Reports, 2021, 11, 16656.	1.6	1
8	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	1.6	1
9	Short-term glucose variability in adults with Type 1 diabetes does not differ between insulin pump and multiple daily injection users – a masked continuous glucose monitoring study in clinical practice. Diabetes and Metabolism, 2020, 46, 172-174.	1.4	2
10	Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 17-26.	5.5	30
11	Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice, 2020, 169, 108450.	1.1	6
12	Estimated insulin sensitivity in Type 1 diabetes adults using clinical and research biomarkers. Diabetes Research and Clinical Practice, 2020, 167, 108359.	1.1	12
13	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3638-e3649.	1.8	37
14	A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 444-455.	1.0	17
15	Higher Serum Sex Hormone–Binding Globulin Levels Are Associated With Incident Cardiovascular Disease in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6301-6315.	1.8	31
16	Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome. Frontiers in Medicine, 2019, 6, 242.	1.2	27
17	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism: Clinical and Experimental, 2019, 93, 93-99.	1.5	24
18	Management of Diabetes Mellitus. Contemporary Cardiology, 2019, , 113-177.	0.0	0

Andrzej Januszewski

#	Article	IF	CITATIONS
19	Attractions and barriers to Australian physicianâ€researcher careers. Internal Medicine Journal, 2019, 49, 171-181.	0.5	12
20	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Internal Medicine Journal, 2018, 48, 1080-1086.	0.5	6
21	Effect of a high-egg diet on cardiometabolic risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) Study—randomized weight-loss and follow-up phase. American Journal of Clinical Nutrition, 2018, 107, 921-931.	2.2	34
22	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clinical Chemistry, 2017, 63, 1261-1270.	1.5	11
23	Early changes of arterial elasticity in Type 1 diabetes with microvascular complications - A cross-sectional study from childhood to adulthood. Journal of Diabetes and Its Complications, 2017, 31, 1674-1680.	1.2	3
24	The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environmental Research, 2017, 158, 366-372.	3.7	35
25	Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications. Diabetic Medicine, 2017, 34, 543-550.	1.2	12
26	Elucidating the Biological Mechanisms Linking Depressive Symptoms With Type 2 Diabetes in Men. Psychosomatic Medicine, 2016, 78, 221-232.	1.3	8
27	Time to research Australian female physicianâ€researchers. Internal Medicine Journal, 2016, 46, 412-419.	0.5	7
28	Time to research Australian physicianâ€researchers. Internal Medicine Journal, 2016, 46, 550-558.	0.5	14
29	Liberal Glycemic Control in Critically III Patients With Type 2 Diabetes: An Exploratory Study. Critical Care Medicine, 2016, 44, 1695-1703.	0.4	49
30	Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study. Metabolism: Clinical and Experimental, 2016, 65, 883-892.	1.5	94
31	Shorter telomeres in adults with Type 1 diabetes correlate with diabetes duration, but only weakly with vascular function and risk factors. Diabetes Research and Clinical Practice, 2016, 117, 4-11.	1.1	17
32	Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 2016, 65, 783-793.	1.5	20
33	Circulating microRNA Biomarkers of Diabetic Retinopathy. Diabetes, 2016, 65, 22-24.	0.3	52
34	Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs. Journal of Visualized Experiments, 2015, , .	0.2	24
35	Biomarkers in Diabetic Retinopathy. Review of Diabetic Studies, 2015, 12, 159-195.	0.5	198
36	Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0137903.	1.1	43

#	Article	IF	CITATIONS
37	A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Scientific Reports, 2015, 5, 10375.	1.6	64
38	The longitudinal association between inflammation and incident depressive symptoms in men: The effects of hs-CRP are independent of abdominal obesity and metabolic disturbances. Physiology and Behavior, 2015, 139, 328-335.	1.0	16
39	Multigenerational Undernutrition Increases Susceptibility to Obesity and Diabetes that Is Not Reversed after Dietary Recuperation. Cell Metabolism, 2015, 22, 312-319.	7.2	83
40	Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 2035-2044.	2.9	25
41	The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 464-473.	2.9	78
42	Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia. Diabetes and Vascular Disease Research, 2014, 11, 262-269.	0.9	10
43	Lipoprotein Glycation in Diabetes Mellitus. Contemporary Diabetes, 2014, , 157-186.	0.0	1
44	Advanced Glycation End Products Acutely Impair Ca2+ Signaling in Bovine Aortic Endothelial Cells. Frontiers in Physiology, 2013, 4, 38.	1.3	18
45	Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: Assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Research and Clinical Practice, 2012, 95, e17-e19.	1.1	25
46	Nonâ€invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a nonâ€invasive measure of vascular dysfunction. Diabetic Medicine, 2012, 29, 726-733.	1.2	44
47	Thioflavin T fluorescence in human serum: Correlations with vascular health and cardiovascular risk factors. Clinical Biochemistry, 2010, 43, 278-286.	0.8	8
48	Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. Journal of Angiogenesis Research, 2010, 2, 19.	2.9	38
49	Increased coatedâ€platelet levels in chronic haemodialysis patients. Nephrology, 2009, 14, 148-154.	0.7	20
50	Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. Journal of Medical Investigation, 2008, 55, 29-36.	0.2	5
51	Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in TypeÂ1 diabetes. Diabetic Medicine, 2007, 24, 1345-1351.	1.2	72
52	The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia, 2007, 50, 643-653.	2.9	122
53	Lipid-Derived Modifications of Plasma Proteins in Experimental and Human Diabetes. Annals of the New York Academy of Sciences, 2005, 1043, 404-412.	1.8	5
54	Plasma Low-Molecular Weight Fluorescence in Type 1 Diabetes Mellitus. Annals of the New York Academy of Sciences, 2005, 1043, 655-661.	1.8	13

#	Article	IF	CITATIONS
55	Chemical modification of proteins during peroxidation of phospholipids. Journal of Lipid Research, 2005, 46, 1440-1449.	2.0	34
56	Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia, 2004, 47, 1385-95.	2.9	76
57	Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochemical Society Transactions, 2003, 31, 1413-1416.	1.6	62
58	The AGE Inhibitor Pyridoxamine Inhibits Development of Retinopathy in Experimental Diabetes. Diabetes, 2002, 51, 2826-2832.	0.3	336